Natural Product-derived Phytochemicals as Potential Inhibitors of Angiotensin Converting Enzyme 2 (ACE2): Promising Drug Candidates for COVID-19

被引:1
|
作者
Palshetkar, Aparna D. [1 ,2 ]
Rasal, Aarti U. [1 ]
Murugan, Aruna [1 ]
Desai, Namita D. [1 ]
机构
[1] SNDT Womens Univ, CU Shah Coll Pharm, Mumbai 400049, India
[2] Vivekanand Educ Soc Coll Pharm, Mumbai 400074, India
关键词
Coronavirus; 2019; SARS-CoV; angiotensin-converting enzyme-2; medicinal plants; phytochemicals; therapeutic use; MEDICINAL-PLANTS; CORONAVIRUS; KINETICS; RENIN;
D O I
10.2174/1574885518666230502103159
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
COVID-19 was deemed a global pandemic by the World Health Organization in February 2020. The prevalence of viral diseases worldwide has increased the importance of receiving immediate medical attention. There is currently no specific medication or vaccine under consideration to treat coronavirus infection. For reducing or preventing COVID-19 infections, a number of alternative therapies are anticipated, including the use of synthetic drugs, vaccines, interferon therapy etc. Due to the serious side effects of the utilized drug therapies, it is crucial to comprehend the pathogenesis of the coronavirus and explore safe and efficient treatment.Considering the contribution of plants and herbs in the management of viruses like HIV, Herpes Simplex, MERS-CoV, and influenza, they can be further utilised for COVID-19 treatment. According to reports, SARS-CoV2 infects host cells through Angiotensin-converting enzyme 2 receptors, causing pneumonia linked to COVID-19 as well as acute myocardial injury and long-term cardiovascular damage. A cure for SARS-CoV2 may lie in understanding the receptor, its targets, and the mechanism of viral replication. This review article highlights several plants that have the potential to inhibit ACE2, including Punica granatum, Citrus aurantium, Allium sativum, Piper longum, Curcuma longa, and Coriandrum sativum as well as their extracts and phytoconstituents, such as flavonoids, alkaloids, anthraquinone glycosides, phenolic acids, and others. This review will provide opportunities for researchers to explore the possibility of developing promising dosage forms that will increase the bioavailability and in vivo effectiveness of the lead candidates.
引用
收藏
页码:13 / 19
页数:7
相关论文
共 50 条
  • [1] Natural Products Modulating Angiotensin Converting Enzyme 2 (ACE2) as Potential COVID-19 Therapies
    Abubakar, Murtala Bello
    Usman, Dawoud
    El-Saber Batiha, Gaber
    Cruz-Martins, Natalia
    Malami, Ibrahim
    Ibrahim, Kasimu Ghandi
    Abubakar, Bilyaminu
    Bello, Muhammad Bashir
    Muhammad, Aliyu
    Gan, Siew Hua
    Dabai, Aliyu Ibrahim
    Alblihed, M.
    Ghosh, Arabinda
    Badr, Reem H.
    Thangadurai, Devarajan
    Imam, Mustapha Umar
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [2] Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19
    Wentao Ni
    Xiuwen Yang
    Deqing Yang
    Jing Bao
    Ran Li
    Yongjiu Xiao
    Chang Hou
    Haibin Wang
    Jie Liu
    Donghong Yang
    Yu Xu
    Zhaolong Cao
    Zhancheng Gao
    Critical Care, 24
  • [3] Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19
    Ni, Wentao
    Yang, Xiuwen
    Yang, Deqing
    Bao, Jing
    Li, Ran
    Xiao, Yongjiu
    Hou, Chang
    Wang, Haibin
    Liu, Jie
    Yang, Donghong
    Xu, Yu
    Cao, Zhaolong
    Gao, Zhancheng
    CRITICAL CARE, 2020, 24 (01)
  • [4] Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19
    Kuba, Keiji
    Yamaguchi, Tomokazu
    Penninger, Josef M.
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [5] Covid-19 and the angiotensin-converting enzyme (ACE2): Areas for research
    Omar, Michael Brandon
    HEART & LUNG, 2020, 49 (04): : 351 - 351
  • [6] Angiotensin-Converting Enzyme 2 (ACE2): Role in the Pathogenesis of Diseases outside of COVID-19
    Mulling, N.
    Rohn, H.
    NEPHROLOGE, 2021, 16 (03): : 185 - 188
  • [7] Is targeting angiotensin-converting enzyme 2 (ACE2) a prophylactic strategy against COVID-19?
    Li, Jing
    Yan, Yufen
    Dou, Fangzhou
    Gao, Jianjun
    BIOSCIENCE TRENDS, 2022, 16 (06) : 459 - 461
  • [8] Angiotensin Converting Enzyme-2 (ACE2) Receptors, asthma and severe COVID-19 infection risk
    Ozturk, A. B.
    Caglayan, B.
    EUROPEAN ANNALS OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 52 (06) : 282 - 285
  • [9] The Impact of Angiotensin-Converting Enzyme 2 (ACE2) Expression on the Incidence and Severity of COVID-19 Infection
    Kaseb, Ahmed O.
    Mohamed, Yehia, I
    Malek, Alexandre E.
    Raad, Issam I.
    Altameemi, Lina
    Li, Dan
    Kaseb, Omar A.
    Kaseb, Safa A.
    Selim, Abdelhafez
    Ma, Qing
    PATHOGENS, 2021, 10 (03):
  • [10] Autoantibodies against angiotensin-converting enzyme 2 (ACE2) after COVID-19 infection or vaccination
    Tsoi, James Yiu Hung
    Cai, Jianpiao
    Situ, Jianwen
    Lam, Winston Jim
    Shun, Estie Hon Kiu
    Leung, Joy Ka Yi
    Chen, Lin Lei
    Chan, Brian Pui Chun
    Yeung, Man Lung
    Li, Xin
    Chan, Kwok Hung
    Wong, Joshua Sung Chih
    Kwan, Mike Yat Wah
    To, Kelvin Kai Wang
    Yuen, Kwok Yung
    Sridhar, Siddharth
    JOURNAL OF MEDICAL VIROLOGY, 2023, 95 (12)